Physostigmine in rigid huntington’s disease

William E. Fann; Carl J. Gerber; G. M. McKenzie

doi:10.1159/000102851

Physostigmine in rigid huntington’s disease

William E. Fann, Carl J. Gerber, G. M. McKenzie

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

3 Citas (Scopus)

Resumen

Physostigmine, a centrally active anticholihesterase agent, was given to three patients with rigid Huntington’s disease (RHD). Neurologic examinations before, during and after the administration showed no change in the manifestations of RHD. The theoretical implications of these data are discussed.

Idioma original	English
Páginas (desde-hasta)	312-315
Número de páginas	4
Publicación	Stereotactic and Functional Neurosurgery
Volumen	35
N.º	5
DOI	https://doi.org/10.1159/000102851
Estado	Published - 1973
Publicado de forma externa	Sí

ASJC Scopus Subject Areas

Surgery
Clinical Neurology

Acceder al documento

10.1159/000102851

Otros archivos y enlaces

Citar esto

@article{6758630131024877985b66ce4c631401,

title = "Physostigmine in rigid huntington{\textquoteright}s disease",

abstract = "Physostigmine, a centrally active anticholihesterase agent, was given to three patients with rigid Huntington{\textquoteright}s disease (RHD). Neurologic examinations before, during and after the administration showed no change in the manifestations of RHD. The theoretical implications of these data are discussed.",

author = "Fann, {William E.} and Gerber, {Carl J.} and McKenzie, {G. M.}",

year = "1973",

doi = "10.1159/000102851",

language = "English",

volume = "35",

pages = "312--315",

journal = "Stereotactic and Functional Neurosurgery",

issn = "1011-6125",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Physostigmine in rigid huntington’s disease

AU - Fann, William E.

AU - Gerber, Carl J.

AU - McKenzie, G. M.

PY - 1973

Y1 - 1973

N2 - Physostigmine, a centrally active anticholihesterase agent, was given to three patients with rigid Huntington’s disease (RHD). Neurologic examinations before, during and after the administration showed no change in the manifestations of RHD. The theoretical implications of these data are discussed.

AB - Physostigmine, a centrally active anticholihesterase agent, was given to three patients with rigid Huntington’s disease (RHD). Neurologic examinations before, during and after the administration showed no change in the manifestations of RHD. The theoretical implications of these data are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84913743876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913743876&partnerID=8YFLogxK

U2 - 10.1159/000102851

DO - 10.1159/000102851

M3 - Article

C2 - 4271422

AN - SCOPUS:84913743876

SN - 1011-6125

VL - 35

SP - 312

EP - 315

JO - Stereotactic and Functional Neurosurgery

JF - Stereotactic and Functional Neurosurgery

IS - 5

ER -

Physostigmine in rigid huntington’s disease

Resumen

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto